Why MiNK Therapeutics Stock Is Up 11% Monday
Why MiNK Therapeutics Stock Is Up 11% Monday
MiNK Therapeutics, Inc. (NASDAQ:INKT) shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million.
MinK Therapeutics, Inc.（納斯達克股票代碼：INKT）股價週一上漲，此前這家處於臨床階段的生物製藥公司宣佈了580萬美元的私募融資。
What Happened: On Monday, MiNK Therapeutics entered into a stock purchase agreement to sell securities in a private investment in public equity (PIPE) agreement. MiNK said it will sell 4.64 million shares at a price of $1.25 per share, representing a 25% premium to current prices.
發生了什麼：週一，MinK Therapeutics簽訂了一項股票購買協議，以私人投資公共股權（PIPE）協議出售證券。MinK表示，它將以每股1.25美元的價格出售464萬股股票，比當前價格高出25％。
The expected total of $5.8 million in financing is earmarked for accelerating the clinical trials of MiNK-215, the company's leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein in solid tumors. The company said it's planned to enter the clinic in early 2025. The PIPE financing agreement is expected to close on May 14, 2024.
預計總額爲580萬澳元的融資將用於加速Mink-215的臨床試驗，Mink-215是該公司領先的針對實體瘤成纖維細胞激活蛋白的同種異體CAR-Inkt細胞療法。該公司表示，計劃於2025年初進入該診所。PIPE融資協議預計將於2024年5月14日結束。
"MiNK-215 is a novel cell therapeutic with the potential to overcome the limitations of traditional immune checkpoint inhibitors in solid tumors," said MiNK CEO Dr. Jennifer Buell.
MinK首席執行官詹妮弗·比爾博士說：“Mink-215是一種新的細胞療法，有可能克服實體瘤中傳統免疫檢查點抑制劑的侷限性。”
"Recent data highlighted MiNK-215's activity to eradicate tumor cells in a model of MSS colorectal cancer with metastatic liver disease, a critical and growing area of unmet need. We are excited to partner with GKCC and committed to advancing our mission of reshaping the cell therapy landscape."
“最近的數據突顯了Mink-215在伴有轉移性肝病的MSS結直腸癌模型中根除腫瘤細胞的活性，這是一個需求未得到滿足的關鍵且不斷增長的領域。我們很高興與GKCC合作，並致力於推進我們重塑細胞療法格局的使命。”
Related Link: 12 Health Care Stocks Moving In Monday's Pre-Market Session
相關鏈接：週一盤前交易時段，12只醫療保健類股票走勢
MiNK also announced the appointment of Yekaterina Chudnovsky as Board Observer. Chudnovsky currently serves as the chairperson of the GI Research Foundation at the University of Chicago Digestive Diseases Center, as well as on the boards of Elicio Therapeutics, Immix Biopharma, XCures and the Colorectal Cancer Alliance.
MinK還宣佈任命葉卡捷琳娜·丘德諾夫斯基爲董事會觀察員。丘德諾夫斯基目前擔任芝加哥大學消化系統疾病中心胃腸道研究基金會主席，以及Elicio Therapeutics、Immix Biopharma、xCures和結直腸癌聯盟的董事會成員。
MiNK Therapeutics is scheduled to release its first-quarter earnings on Tuesday morning. Analysts are anticipating an EPS loss of 15 cents, per Benzinga Pro.
MinK Therapeutics計劃於週二上午發佈其第一季度業績。根據Benzinga Pro的數據，分析師預計每股收益將虧損15美分。
INKT Price Action: According to Benzinga Pro, MiNK Therapeutics shares are up 11.1% at $1 at the time of publication.
INKT價格走勢：根據Benzinga Pro的數據，在發佈之時，MinK Therapeutics的股價上漲了11.1％，至1美元。
Image: Pixabay.
圖片：Pixabay。
譯文內容由第三人軟體翻譯。